Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for filgrastim

  1. Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

    In development [GID-TA11496] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  3. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

    Technology appraisal guidance
    Published
    21 February 2024
    View recommendations

    Sections for TA952

  4. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued [GID-TA10070]

    Technology appraisal guidance
    Discontinued

  5. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued [GID-TA10363]

    Technology appraisal guidance
    Discontinued

  6. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA887